Cargando…
Olopatadine ophthalmic solution suppresses substance P release in the conjunctivitis models
BACKGROUND: Olopatadine hydrochloride ophthalmic solutions are treated for allergic conjunctival diseases that are a selective histamine H1 receptor antagonist and an inhibitor of the release of mediators including histamine from the human mast cells. Substance P (SP) levels are increased in tears o...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asia Pacific Association of Allergy, Asthma and Clinical Immunology
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3345324/ https://www.ncbi.nlm.nih.gov/pubmed/22701861 http://dx.doi.org/10.5415/apallergy.2012.2.2.115 |